New research that our supporters have made possible
NBCRC remain extremely grateful to all our supporters. 100% of the donations we receive goes towards supporting our research, helping us to improve our understanding of breast cancer and develop novel therapies.
The new research that our supporters have made possible, through the allocation of pilot grants, are listed below. Each of these projects has been awarded £10K which, over a period of 12 months, is used to generate essential data, data which will lead to research publications to share our discoveries with the community at large, and strengthen larger grant applications to external funding bodies (major charities and government). One may lead to the next breakthrough!
The pilot grant application process is extremely rigorous and involves an external panel of internationally recognised breast cancer experts to ensure that only the very best projects are funded. We also take into account the views and preferences of a panel of breast cancer patients. With your support we would like to continue to offer these awards on an annual basis.
To keep up to date with the exciting results of the projects follow us on social media, keep an eye on our regular newsletters, or come along to one of our public awareness events.
2024
Professor Alan Mcintyre - Investigating spatially resolved metabolic and RNA-SEQ profiles of triple negative breast cancer brain metastases
Dr Cinzia Allegrucci - Overcoming secondary breast cancer with combination epigenetic therapy
2023
No Grants Allocated
2021
Jennifer Ashworth - Targeting invasive heterogeneity in breast cancer using methods from wound healing
James Dixon - Acidosis-inducible drug and label delivery as a breast cancer therapeutic
Cinzia Allegrucci - Discovering drivers of breast cancer recurrence to overcome metastatic disease
2020
Tracey Bradshaw - Investigating in vivo efficacy of apoferritin-encapsulated antitumour benzothiazole 5F203 against human-derived breast cancer xenografts
Victoria James - Uncovering how triple negative breast cancer communicates to nearby non-cancer cells in order to mediate treatment resistance
Stewart Martin - Understanding calpastatin’s role in regulating breast cancer metastasis
2019
Judith Ramage - Tissue Resident immune cells in Breast Cancer
Srinivasan Madhusudan - Targeting Replication protein A (RPA) for personalization of breast cancer therapy
Andy Green - Glutaminase is a key therapeutic target in luminal breast cancer
Recent Publications & Grant Success
Lashen AG, Wahab N, Toss M, Miligy I, Ghanaam S, Makhlouf S, Atallah N, Ibrahim A, Jahanifar M, Lu W, Graham S, Bilal M, Bhalerao A, Mongan NP, Minhas F, Raza SEA, Provenzano E, Snead D, Rajpoot N, Rakha EA. Characterization of Breast Cancer Intra-Tumor Heterogeneity Using Artificial Intelligence. Cancers (Basel). 2024 Nov 16;16(22):3849. doi: 10.3390/cancers16223849. PMID: 39594804; PMCID: PMC11593220.
Bhattarai S, Rupji M, Chao HP, Xu Q, Saini G, Rida P, Aleskandarany MA, Green AR, Ellis IO, Janssen EA, Jonsdottir K, Rakha E, Kowalski J, Aneja R. Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer. BJC Rep. 2024 Nov 13;2(1):87. doi: 10.1038/s44276-024-00097-z. PMID: 39537757; PMCID: PMC11561184.
Erkan B, MacIntyre S, Brown C, Fakroun A, Lashen AG, Mongan NP, Ellis IO, Rakha EA, Green AR. Hydroxyacid Oxidase 1, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Luminal Breast Cancer. Int J Mol Sci. 2024 Oct 28;25(21):11572. doi: 10.3390/ijms252111572. PMID: 39519124; PMCID: PMC11545845.
Sibbering M, Rogers V, Merriman L, Azmy I, Stafford D, Clifton K, Pickard J, Bartholomeuz T, Robertson J. Community breast pain clinics can provide safe, quality care for women presenting with breast pain. BMJ Open Qual. 2024 Oct 30;13(4):e002882. doi: 10.1136/bmjoq-2024-002882. PMID: 39477240; PMCID: PMC11529464.
Gomes F, Farrington N, Pearce J, Swinson D, Welford J, Greystoke A, Baxter M, Brown-Kerr AG, Wyld L, Morgan J, Battisti NML, Barrell A, Cobben D, Cree A, Johnston M, Colquhoun K, Phillips I, Smith J, Stapley S, Lyons L, Balachandran K, Brown H, Bryce R, Dacie R, Parks R, Denholm M, Harari D, Rigden T, Sommer D, Williams K, Worby K, Cheung KL. The care of older patients with cancer across the United Kingdom in 2024: A narrative review by the International Society of Geriatric Oncology UK Country Group. J Geriatr Oncol. 2024 Oct 24:102133. doi: 10.1016/j.jgo.2024.102133. Epub ahead of print. PMID: 39455366.
Giannotti E, Sun R, Healy N, Kilburn-Toppin F, Sofia C, Lee AH, Marino MA. Assessment of pediatric breast ultrasound less is more: a practical imaging approach. Acta Radiol. 2024 Oct 15:2841851241287924. doi: 10.1177/02841851241287924. Epub ahead of print. PMID: 39410773.
Ghannam SF, Rutland CS, Allegrucci C, Mather ML, Alsaleem M, Bateman-Price TD, Patke R, Ball G, Mongan NP, Rakha E. Geometric characteristics of stromal collagen fibres in breast cancer using differential interference contrast microscopy. J Microsc. 2024 Oct 3. doi: 10.1111/jmi.13361. Epub ahead of print. PMID: 39359124.
Gemma C, Lai CF, Singh AK, Belfiore A, Portman N, Milioli HZ, Periyasamy M, Raafat S, Nicholls AJ, Davies CM, Patel NR, Simmons GM, Fan H, Nguyen VTM, Magnani L, Rakha E, Martin LA, Lim E, Coombes RC, Pruneri G, Buluwela L, Ali S. Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer. Cancer Res. 2024 Oct 2:10.1158/0008-5472.CAN-24-0013. doi: 10.1158/0008-5472.CAN-24-0013. Epub ahead of print. PMID: 39356622; PMCID: PMC7616691.
Lee AHS, Hodi Z, Abbas A, Ellis IO, Rakha EA. HER2-positive grade 1 invasive carcinomas of the breast. Histopathology. 2024 Sep 11. doi: 10.1111/his.15315. Epub ahead of print. PMID: 39257304.